Ubiquitin trailblazer elected Fellow of prestigious Royal Society
Posted: 20 May 2024 WEHI division head and pioneer of ubiquitination Professor David Komander has been elected a Fellow of the esteemed Royal Society, the UK’s national science academy. Prof Komander was recognised for his significant research contributions towards understanding…
Nominations Open For Manufacturing Hall Of Fame
Posted: 20 May 2024 Victoria’s most advanced and innovative manufacturers are being encouraged to nominate for the 2024 Victorian Manufacturing Hall of Fame Awards, supported by the Allan Labor Government. Minister for Jobs and Industry Natalie Hutchins today…
Amplia Therapeutics Successfully Completes $4.27 million Fully Underwritten Entitlement Offer and ACCENT Trial Update
Posted: 15 May 2024 Amplia Therapeutics Limited (ASX: ATX) (Amplia or the Company) is pleased to announce the successful completion of its $4.27 million fully underwritten, non-renounceable entitlement offer which was well supported by existing eligible shareholders and…
Federal Budget 2024-2025 update for our biotechnology industry
Posted: 15 May 2024 With the delivery of last night’s Federal Budget, below is a summary of the key announcements impacting our industry. This is the third Budget delivered by the Albanese Government, and their final before the…
BioBeacon 2024: ARCS Australia Landmark Event to Spotlight Life Sciences Startups Register to attend!
Posted: 14 May 2024 Closes: 22 April 2024 Event: 14 June 2024 ARCS Australia Ltd, the peak organisation dedicated to the advancement of professionals in the MedTech, Biotech and Pharmaceutical sector, is thrilled to announce the inaugural BioBeacon…
Novartis, Monash University and Monash Health partner in bold vision for heart health
Posted: 14 May 2024 Today, Monash University, Monash Health and Novartis announced a unique Australian partnership in the fight against cardiovascular disease – Australia’s most significant health challenge responsible for 1 in 4 deaths and claiming an Australian life every 12 minutes.…
Cellular immunotherapy manufacturer secured – Cell Therapies
Posted: 14 May 2024 AdAlta Limited (ASX:1AD) (AdAlta) and Cell Therapies Pty Ltd (CTPL) are pleased to announce that they have executed a Master Services Agreement (MSA) establishing CTPL as AdAlta’s preferred manufacturing partner of cellular immunotherapies. This…
Optiscan Signs Know-How Agreement with Mayo Clinic
Posted: 14 May 2024 Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘The Company’) is pleased to announce that it has entered into a collaboration through a know-how agreement (Agreement) with Mayo Clinic to develop a digital confocal laser endomicroscopic…
Landmark accelerator program launched at Burnet Institute
Posted: 13 May 2024 Burnet Institute is investing an initial $6.5 million in a landmark accelerator program – Burnext – designed to fast-track research into real-world outcomes to improve human health. Burnext will take research projects through an…
Crux Biolabs and KCAS Bio announce Global Spectral Flow Cytometry Alliance
Posted: 13 May 2024 KCAS Bio has selected Crux Biolabs (Melbourne, Australia) as its partner in providing harmonised spectral flow cytometry across the US, Europe, and Australia. The alliance enables KCAS Bio and Crux Biolabs to support the…
Funding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential
Posted: 8 May 2024 CUREator by Brandon BioCatalyst has announced the deployment of $7.21 million in funding to support eight biotech companies across their Clinical and Preclinical streams thanks to the Federal Government’s Medical Research Future Fund’s Early-Stage…
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Posted: 8 May 2024 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its…
